AlphaMadera's AlphaVal page computes Bio-Techne Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag TECH as undervalued, fairly valued, or overvalued.

What is Bio-Techne Corporation's fair value?

Fair value for TECH is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value TECH?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from TECH's most recent reported fundamentals.

TECH - Bio-Techne Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $60.33 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 80% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 52.1% above fair value

Current Price $48.21

Bear Case $24.51 49.2% downside ($24.51 - $48.21) / $48.21 = -49.2% 5% stage 1 growth, 12% discount

Fair Value $31.69 34.3% downside ($31.69 - $48.21) / $48.21 = -34.3% 8% stage 1 growth, 12% discount

Bull Case $38.41 20.3% downside ($38.41 - $48.21) / $48.21 = -20.3% 11% stage 1 growth, 12% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

8.2%

Discount Rate (WACC)

12.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (8% base case)

Terminal Value % of EV 33%

Implied Market Multiple 34.7x

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $60.33 from 25 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $31.69 per share.

Warnings

⚠ Stock-based employee pay equals 56% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

ℹ Wall Street's average price target is $60.33 (from 25 analysts). Our estimate is 63% below the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions